Home > Browse Research > Life Sciences > Pharmaceuticals > Biopharmaceuticals

Biopharmaceuticals: market research reports

Biosimilars (129)

Biopharmaceuticals market research reports and industry analysis

HGH Biosimilars Market Forecast to 2015 5/1/2012 \| published by: RNCOS ... state. In our latest report, it has been estimated that the global biosimilars market will expand at a CAGR of around 52% during 2010-2015. As the governments and private players around the world are stepping ... \| read more...	$300.00
9th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 4/30/2012 \| published by: BioPlan Associates, Inc. ... assessment of manufacturing capacity and production in this $145 billion global industry. You will find current, quantitative information from 302 worldwide biopharmaceutical developers and contract manufacturers, and 185 suppliers to the industry. Coverage includes: In-depth ... \| read more...	$895.00
Erythropoietin Market in Japan 2011-2015 4/27/2012 \| published by: Infiniti Research Limited ... in Japan has also been witnessing the R&D activities for the application of erythropoietin in neurological disorders. However, the delayed approval process for biosimilars of erythropoietin in Japan could pose a challenge to the growth ... \| read more...	$1,500.00
Single-Use Bioreactors for Pharma: World Market 2012-2022 4/18/2012 \| published by: Visiongain ... prospects. Biological drugs - novel and follow-on biologics (biosimilars) - are changing pharma and supporting industries. How will bioreactor manufacturers and related suppliers seize opportunities from 2012 to 2022? You find answers in our study. ... \| read more...	$2,739.00
Systemic Lupus Erythematosus: Which Clinical Attributes Will Most Effectively Position Emerging Biologics Against Belimumab in the Moderate to Severe Patient Segment? 4/11/2012 \| published by: Decision Resources ... the autoimmune reactions that characterize the disease. In 2011, IV belimumab (Human Genome Sciences/GlaxoSmithKline’s Benlysta) became the first drug approved for SLE in more than 50 years, highlighting the difficulty in treating this multifactorial disease. ... \| read more...	$10,000.00
Innovative R&D and Dealmaking Opportunities: Immune and Inflammatory Disease Biologics 4/5/2012 \| published by: Decision Resources ... many autoimmune and inflammatory diseases and a key driver of market growth. Big Pharma companies are looking to small discovery and technology firms to find the innovation required for next-generation agents. Numerous programs are in ... \| read more...	$10,000.00
Biosimilars 4/1/2012 \| published by: Global Industry Analysts ... report profiles 55 companies including many key and niche players such as Biocon Ltd., Biopartners GMBH, Cipla Ltd., Dr. Reddy's Laboratories Ltd., Hospira, Inc., Intas Biopharmaceuticals Ltd., Sandoz International GmbH, Shantha Biotechnics Ltd., Teva Pharmaceutical ... \| read more...	$4,500.00
Research Report on Chinese Bio-pharmaceutical Industry, 2012 3/21/2012 \| published by: China Research and Intelligence Co., Ltd. ... bio-pharmaceutical industry. "Bio-pharmaceutical" in the report only refers to human biological products. Chinese biological product industry is an emerging industry which has only over 20 years of history. In 2011, the sales revenue of Chinese ... \| read more...	$3,000.00
Regulatory Intelligence on Biologics Recalls – Immunoglobulins and Vaccines are Involved in More Recalls than Other Drug Classes 3/14/2012 \| published by: GBI Research ... Recalls than Other Drug Classes”, provides in-depth analysis of biologics recalls issued or reported with the US Food and Drug Administration (FDA) and its constituent agencies. The report analyzes biologics recalls on the basis of ... \| read more...	$3,500.00
Biologics Market in Brazil 3/2/2012 \| published by: Frost & Sullivan ... growth hormones, and erythropoietin is provided. This service also highlights key market drivers and restraints in addition to breaking down the current and forecasted competitive scenario. The base year of the study is 2010, and ... \| read more...	$6,000.00
The US Pharmaceutical Market Outlook to 2016 - Evolving Opportunities in the Biologics Segment 3/1/2012 \| published by: Ken Research ... as market size of the pharmaceutical industry, market segmentation by Branded and Generic drugs, and Prescribed and OTC drugs and Biologics and specialty drugs segments. The report also provides information on the government regulations, export ... \| read more...	$595.00
Global Biosimilars Market Forecast to 2015 3/1/2012 \| published by: RNCOS ... evolve greatly from its current state. As per the estimations of our latest report, the global biosimilars market will grow at a CAGR of around 52% during 2010-2015. With the governments and private players worldwide ... \| read more...	$1,500.00
Biosimilars: Current Situation & Future Prospects, Worldwide 3/1/2012 \| published by: JustPharmaReports.com ... biologics market expected to lose some degree of protection by 2019. All major countries now make provision for an abbreviated biosimilar development and regulatory pathway. Funds are flowing into the sector and many new partnership ... \| read more...	$3,000.00
TreatmentTrends®: Biologics in Crohn's Disease (US) 2012 2/29/2012 \| published by: Decision Resources ... market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, and sales force performance. Please note, the PDF e-mail from publisher version of this report is for a global site license. \| read more...	$15,000.00
World Biological Drugs Market 2012-2022 2/14/2012 \| published by: Visiongain ... you assess potential sales trends at world market, submarket, product and regional level to 2022. How will 20 leading biologics - including Avastin, Enbrel, Humira and Herceptin - perform from 2012? Our investigation gives you ... \| read more...	$2,739.00
Global Biosimilar Market 2010-2014 2/10/2012 \| published by: Infiniti Research Limited ... of branded biopharmaceuticals. The Global Biosimilar market has also been witnessing the trend of outsourcing of biosimilar manufacturing to Asian countries. However, the risk of drug development failure could pose a challenge to the growth ... \| read more...	$1,500.00
Oncology Partnering Terms and Agreements 2/1/2012 \| published by: Current Partnering ... analysis of how and why companies enter oncology partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors oncology technology. ... \| read more...	$2,995.00
Competitor Analysis: Anti-Obesity Peptides and Biologics 2/1/2012 \| published by: La Merie Publishing ... 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. The database also contains information about discontinued projects. Credentials to ... \| read more...	$262.00
Global Biosimilars: A return to optimism? 1/23/2012 \| published by: Espicom Healthcare Intelligence Despite some commentators predicting a muted or near nonexistent market for advanced biosimilars, many companies – and some surprising names – are positioning themselves for market entry. \| read more...	$2,265.00
2011 Biotechnology Research Review 1/1/2012 \| published by: BCC Research ... $8.4 billion by 2016, increasing at a compound annual growth rate (CAGR) of 18.8%. The global biobanking market was $141 billion in 2010 and is projected to expand by 30% between 2010 and 2015, increasing ... \| read more...	$950.00
Strategies for Entering the Biosimilars Market 12/21/2011 \| published by: Business Insights ... Strategies employed by a diverse range of companies to enter the biosimilars market enable conclusions to be drawn on key factors for success in this sector. Features and benefits Appreciate the regulatory, clinical, and commercial ... \| read more...	$3,835.00
Biosimilars: Market Entry Strategies 12/20/2011 \| published by: Datamonitor ... low risk. One such area is biosimilars, which has attracted both innovative biologics players and generics players alike. Features and benefits Insight into why pharma are tapping into the biosimilars market Analysis of biosimilar deal ... \| read more...	$5,700.00
Analysis of European Biosimilars Market 12/20/2011 \| published by: Frost & Sullivan ... participants. This study is focused on established segments in Europe including Erythropoietin, Granulocyte Colony Stimulating Factors, Human Growth Hormones and emerging segments including monoclonal antibodies, Insulin and interferon. The established market segments consist of products ... \| read more...	$6,500.00
Specialty Physicians Discuss their Opinions of the United States Biosimilars Market 12/8/2011 \| published by: Frost & Sullivan ... and expectations of specialty physicians who would be expected to be among the first customers of biosimilars, with the objective of gaining insight into some of the major factors which could influence market uptake. The ... \| read more...	$10,000.00
Market and Product Forecasts: Psoriasis – Novel products and current biologics to fuel future market growth 11/30/2011 \| published by: Datamonitor ... is trailblazing the US and EU markets, threatening both brands. By 2020, biosimilars, generics and four product launches will grow the market to $5.5bn. Introduction Access Datamonitor’s patient based psoriasis market forecast of over 50 ... \| read more...	$11,400.00

< prev 1 2 3 4 5 6 7 8 9 10 next >